Articles Raising the bar: can Gilead’s next challenge be even bigger ... How do you follow a genuine drug breakthrough, a cure for hepatitis C?
Articles NICE calls the shots on Harvoni – but NHS England eyeing pri... Harvoni and rival hep C drugs look set for approval in England – but NHS England may have the last word on controlling costs, finds Andrew McConaghie.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
